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Abstract
Background
Understanding the costs associated with health care delivery strategies is essential for plan-
ning. There are few data on health service resources used by patients and their associated
costs within antiretroviral (ART) programmes in Africa.
Material and methods
The study was nested within a large trial, which evaluated screening for cryptococcal
meningitis and tuberculosis and a short initial period of home-based adherence support for
patients initiating ART with advanced HIV disease in Tanzania and Zambia. The economic
evaluation was done in Tanzania alone. We estimated costs of providing routine ART ser-
vices from the health service provider’s perspective using a micro-costing approach. Incre-
mental costs for the different novel components of service delivery were also estimated. All
costs were converted into US dollars (US$) and based on 2012 prices.
Results
Of 870 individuals enrolled in Tanzania, 434 were enrolled in the intervention arm and 436 in
the standard care/control arm. Overall, the median (IQR) age and CD4 cell count at enrol-
ment were 38 [31, 44] years and 52 [20, 89] cells/mm3, respectively. The mean per patient
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costs over the first three months and over a one year period of follow up following ART initia-
tion in the standard care arm were US$ 107 (95%CI 101–112) and US$ 265 (95%CI 254–
275) respectively. ART drugs, clinic visits and hospital admission constituted 50%, 19%,
and 19% of the total cost per patient year, while diagnostic tests and non-ART drugs (co-tri-
moxazole) accounted for 10% and 2% of total per patient year costs. The incremental costs
of the intervention to the health service over the first three months was US$ 59 (p<0.001;
95%CI 52–67) and over a one year period was US$ 67(p<0.001; 95%CI 50–83). This is
equivalent to an increase of 55% (95%CI 51%–59%) in the mean cost of care over the first
three months, and 25% (95%CI 20%–30%) increase over one year of follow up.
Background
Over 12 million HIV-infected people now have access to antiretroviral therapy (ART) in Africa
[1] where there are severe constraints on health care resources, in particular, a severe shortage
of health care workers. Understanding the costs associated with different approaches to health
care delivery is essential to inform policy, and especially important in resource-limited settings
[2]. Despite this, there are surprisingly few published studies describing the costs of ART pro-
grammes in low income countries in Africa [3].
Costing studies use either the “top-down” or “bottom-up” approach or a combination of
these [4,5]. The former estimates costs by dividing the past expenditure by the number of ser-
vices provided during the period that expenditure was incurred. These analyses are crude and
it is not possible to assess how patient characteristics influence costs and or the extent to which
costs vary between settings. The “bottom up” approach, also referred to as the ingredient-
based approach, quantifies the inputs used to provide the service outputs. Micro-costing is a
form of “bottom up” approach and is essential for evaluating new interventions [4,6,7] as it
allows for the statistical analysis of the key cost drivers at the individual level. Since 2003, just
four published HIV costing studies from low income sub-Saharan Africa have used an individ-
ual level micro-costing approach, but all were retrospective [8–11] and their findings are now
outdated [12–16].
Materials and methods
In this study, we estimated the costs of ART delivery in the primary care setting in Tanzania
using a micro-costing approach. Our study was nested within a trial, which aimed to reduce
HIV-mortality among patients presenting in the very advanced stages of HIV-infection
(REMSTART) [17]. Half of the participants received routine standard care. The other half
received routine standard care combined with additional screening and adherence support.
The participants were managed by health care staff according to national guidelines so that the
trial provided an opportunity to estimate costs of real-life ART care in an urban setting. We
analysed the resource use and costs of ART in both the routine health services and with the
added intervention within REMSTART [17].
Study settings
The REMSTART trial was implemented in Dar es Salaam, Tanzania, and Lusaka, Zambia, but
the cost study was restricted to Tanzania for logistical reasons. Dar es Salaam has an estimated
population of 4.4 million people [18] and an HIV prevalence among 15–49 year old of 6.9%
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[19]. The city is divided into three districts—Kinondoni, Ilala and Temeke. The trial was
implemented at three government-run primary care health centres, one in each district (Tan-
dale in Kinondoni, Buguruni in Ilala and Mbagala Rangi Tatu in Temeke).
In Tanzania, HIV is managed largely from primary care clinics. National guidelines at the
time of the study were that patients presenting with a diagnosis of HIV-infection should have
beeen offered ART if they had a CD4 count 350 cells/mm3 or if they were at WHO clinical
stages 3 or 4 [20]. Follow-up clinic visits were initially every month and then two-monthly,
when the patient was considered stable on therapy according to the clinician’s assessment.
The REMSTART trial was restricted to patients who presented with advanced disease because
they have very high rates of mortality [21–24]. Initially, patients with CD4 count<100 cells/
mm3 were enrolled, but this criteria was changed subsequently to enrol patients presenting
with< 200 cells/mm3, in order to speed up recruitment [17].
Participants were individually randomised [17] to receive either routine care or routine
care plus additional clinic and community-based services (the REMSTART intervention). All
participants (in both arms) were screened for tuberculosis (TB), irrespective of symptoms and
tested for TB using GeneXpert1MTB/RIF assay (Cepheid, Sunnyvale, USA) (hereon referred
to as Xpert) and ART was initiated rapidly where possible. Fig 1 shows both the pathway for
and services provided to individuals in intervention and standard care arms. At the time of the
trial implementation, Xpert was not part of standard care but all particpants were tested for TB
using Xpert because it had been endorsed by the WHO as a screening tool for TB. Apart from
screening for TB using Xpert test, study partcipants in the routine care arm were managed
according to the standard of care. The clinic plus community support arm received the follow-
ing additional services: i) screening for cryptococcal infection using serum cryptococcal anti-
gen combined with pre-emptive fluconazle therapy for patients testing antigen positive; ii)
weekly home visits for the first 4 weeks on ART by trained lay workers to provide adherence
Fig 1. Pathway of care for HIV-infected individuals presenting in with CD4 count < 200 cells/mm3 in intervention and standard care
arms in Tanzania. *Under standard care, TB screening is done using smear microscopy examination or chest x-ray. For this study, Xpert
screening was used in both arms at baseline.
doi:10.1371/journal.pone.0171917.g001
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support; and (iii) re-screening for tuberculosis using the Xpert test at 6–8 weeks after ART ini-
tiation in participants in whom tuberculosis was not diagnosed at enrolment [17] (Fig 1).
Data collection
Participants were recruited from February 2012 to September 2013, and each participant was
followed for up to 1 year. Resource use and costs were measured from a provider’s perspective
using a micro-costing approach. Health service resource use by the patient was tracked in trial
records over a one year period for both patients under routine care and those in the clinic plus
community plus support arms. This included number of clinic visits made by the patient, lay-
worker home visits, diagnostic screening and treatment and inpatient costs. Cost data were
collected as described in the supporting information (S1 Table) which lists the data collected
and methods of collection at each of the sources. Costs were classified as recurrent or capital.
Allocation of costs. The time medical staff spent on different types of clinic visits was esti-
mated using patient observations conducted over a one week period and personnel diaries self-
completed by individual staff. Clinic visits were categorised as follows: i) a visit during which a
clinical examination and CD4 count testing were done, ii) a visit during which the patient was
assessed for ART eligibility, iii) a visit in which a patient self-referred to the clinic and was seen
by clinician (sick visit), (iv) a visit during which a patient was clinically re-assessed following
ART initiation and CD4 count testing was repeated, and v) a routine visit for the collection of
drugs alone. Staff time spent on other activities was allocated to each visit in proportion to the
daily patient contact time derived from personnel diaries. Such activities included morning
report meetings, tea and lunch breaks, cleaning and preparing daily reports. As the clinic pro-
vides dedicated paediatric care on one day per week, 80% (4 out of 5 working days) of the
shared costs were allocated to adult care. These costs were then divided by the average number
of adult visits per month to obtain the cost per patient visit. Personnel time for laboratory work
and lumbar punctures was derived from staff interviews. The laboratory equipment-related cost
was calculated per test by dividing the annualised cost by the number of tests done. Research
costs were excluded.
Costs incurred outside the clinic, other than laboratory costs, such as administrative costs,
were not available for this study. Administrative costs reported elsewhere in resource limited
settings ranged between 3% and 15.5% of the total costs of care [25,26]. Thus, we assumed an
administrative cost of 10% of the clinic visit costs.
Cost valuation. All prices were converted to 2012 prices using the GDP deflator [27] and
converted to US dollars (US$) (Exchange rate: 1US$ = 1,573.70 Tanzanian shillings -Tzshs)
[28]. The annualization of capital costs, including training, was done using a discount rate of
7.8% equal to the 2-year Tanzanian government bond (at the time of calculation, June 2014)
[29]. The annualization is the process of spreading the current purchase price of each item of
equipment across its working life, taking into account its opportunity cost. The expected useful
life for equipment varied from 3 to 15 years depending on the item [30]. Training of the lay-
workers was estimated to have a life span of 3 years.
Analysis
Total and average resource use and costs per patient were estimated by month, quarter and
year using time-series commands in Stata 13.0 (StataCorp). Costs were calculated separately
for the routine care arm and then for the intervention arm. The denominator for the mean
costs at all time points is all randomised patients rather than the those patients who were still
alive at each time point.
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Generalised linear regression analyses. We calculated a mean cost per patient (for 1 year
of treatment) and used univariate and multivariate linear regression to explore the influence of
study site [30], severity of illness (level of CD4 count and WHO clinical stage), marital status,
level of education, gender and age [31–34] on the mean cost of HIV/AIDS care among those
who received standard care.
Sensitivity analyses. To account for uncertainty in some of the key variables, univariate
sensitivity analyses were done in which parameters were varied one at a time using values
given in the supporting information (S2 Table). The discount rate was varied to ensure compa-
rability with other studies [35]. Prices for ART, reagents and the Xpert cartridges were varied
to explore the impact of any changes in the international market prices. Costs incurred above
the clinic level were varied to reflect the uncertainty in the baseline estimate. In addition, the
analysis was run replacing the cost of the Xpert with a cost for smear microscopy, given the
limited use of the Xpert to date in sub-Saharan Africa. The transportation costs of Xpert spu-
tum samples (from the clinics to the central tuberculosis reference laboratory where Xpert
machines are located) are critical to cost-effectiveness of a programme [25], therefore this
transport cost was varied to reflect any uncertainty in replicating the trial transport mecha-
nism. Further, the number of home visits per day by a lay worker was varied from the base
case scenario to a more likely work load scenario in a real life setting in which more home
visits would be conducted. Detailed methods for the sensititivity analysis can be found in the
supporting information (S2 Table). The uncertainty analyses were based on most likely, mini-
mum and maximum values.
Ethics statement. The study was nested within a large trial (ISCRTN 20410413) which
was approved by the ethics committee of the London School of Hygiene & Tropical Medicine,
the Ethics and Research Science committee in Zambia, and the National Health Research Eth-
ics Sub-Committee in Tanzania. All study participants were older than 18 years and each pro-
vided a written informed consent.
Results
Characteristics of the study participants in Tanzania
A total of 870 individuals, 436 in standard care arm and 434 in the intervention arm, were
enrolled in the study. The median (IQR) age of patients was 38 [31,44] years, 62% were female,
and the median (IQR) CD4 cell count at enrolment was 52 [20,89] cells/mm3 (Table 1). Over-
all, the median (IQR) length of follow up was 333 (347, 365) days. The majority of participants
were initiated on TDF-containing (60%) or AZT-containing (36%) ARV regimens. Overall,
after a year of follow up, 684 (78.6%) participants were alive and receiving care at the study
clinics, 153 (17.6%) had died, 8 (0.9%) had withdrawn from the study and survival status for
25 (2.9%) participants was unknown. Sixty six of 153 (43.1%) participants who had died were
from the intervention arm. Overall, 22 (5%) of the 434 participants screened for cryptococcal
antigen in the intervention group tested positive for serum cryptococcal antigen.
Unit costs for different components of HIV care
Table 2 presents estimates of unit costs, at each clinic, for the different components of ART
services. The mean clinic cost for outpatient visits ranged between US$ 5.76 for a drug collec-
tion visit without clinical assessment to US$ 6.74 for a visit that included a clinical assessment
and a CD4 count test. The cost of a home visit conducted by a lay-worker was $14.74. The cost
of diagnostic tests ranged between US$19.07 for an Xpert test and US$ 0.31 for a creatinine
test. The novel CrAg test was estimated to cost $3.96 per participant.
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Costs for personnel and non-medical material plus supplies constituted more than 60% and
13% respectively of the unit costs for out-patient clinic visits, excluding diagnostic procedures.
Costs of the reagents for CD4, CrAg and Xpert were 85%, 99% and 70% of the unit costs for
these tests (see S3 Table). There was little variation between the clinics in the breakdown of
costs (Table 2).
Resource utilization
Table 3 summarizes the information on resources used by the study participants. Seventeen
individuals (7 randomised to standard care and 10 to the intervention arm) of 870 (2%) did
not start ART. Twelve of these individuals died soon after presentation, 1 was lost to follow up
and 4 withdrew from the study before starting ART.
Of 436 patients in the standard care arm, 270 (62%) completed one year of follow up, which
was defined as those individuals who were alive and receiving care at one of the study clinics,
66 (15%) had died, 60 (13.8%) did not return to a study site at 12 months, 37 (8.5%) withdrew
from the study and information for 3 participants was missing. Overall, the study participants
in the standard care arm spent 308.9 person years in ART care, equivalent to a mean follow up
on ART of 0.71 year per patient. Of the total time on treatment, 62% and 37% was spent on
ART regimens containing TDF and AZT, respectively; and 1% was spent on other regimens.
Thirty of 429 (7%) patients who initiated on ART substituted at least one drug in their regimen
during the one-year period of follow up. Patients in the standard care arm were on co-trimoxa-
zole for a mean of 0.73 years during the study period.
In the intervention arm, 289/434 (66.6%) patients completed one year of follow up. Of
those who continued to receive care from the study clinics, 51/434 (12%) had died, 36/434
(8%) did not return to a study clinic, 56/434 (13%) withdrew from the study and information
for 2 participants was missing. Overall, the study participants in the intervention arm spent
316.4 years in ART care, equivalent to a mean follow up on ART of 0.73 year per patient. Of
the total time on treatment, 64% and 34% was spent on ART regimens containing TDF and
Table 1. Characteristics, HIV disease progression and ART treatment regimen of for study participants (HIV patients presenting in the advanced
stages of HIV-infection—CD4 <200cells/mm3), in Dar es Salaam, Tanzania.
Characteristics Study sites
Buguruni Tandale Mbagala All sites
Sample size 196 280 394 870
Standard (control) arm 99 140 197 436
Intervention arm 97 140 197 434
Sex
Male n(%) 58 (29.6) 105 (37.5) 164 (41.6) 327 (37.6)
Age at enrolment mean (SD) 39.1 (10.4) 37.4 (8.6) 39.2(9.9) 38.6 (9.7)
CD4 cells/mm3, median (min, max) 52 (2, 189) 57.5 (1, 199) 47 (1, 199) 52. (1, 199)
ARTa regimen initiated at enrolment n(%)
d4T-containing regimen 0 (0.00) 0 (0.00) 10(2.54) 10 (1.15)
AZT-containing regimen 68 (34.69) 146 (52.14) 100 (25.38) 314 (36.09)
TDF -containing regimen 125 (63.78) 127 (45.36) 269 (68.27) 521 (59.89)
ABC -containing regimen* 2 (1.02) 5 (1.79) 1 (0.25) 8 (0.92)
Did not initiate on ART 1 (0.51) 2 (0.71) 14 (3.55) 17 (1.95)
aART—Antiretroviral Therapy; ABC—abacavir; TDF—tenofovir disoproxil fumarate AZT—zidovudine; d4T –stavudine
*ABC is the nucleoside reverse transcriptase inhibitors (NRTIs) used as the second line drugs for adult and adolescents in Tanzania.
doi:10.1371/journal.pone.0171917.t001
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Table 2. Unit costs (in 2012 US$) of the different components of ART services for patients initiating treatment with CD4 count <200 cells/mm3 in
Dar es Salaam, Tanzania.
Variable Unit cost (2012 US$) (per patient)
Buguruni Mbagala Tandale Mean cost for all sites
Costs for clinic outpatient visits under ART programme
Initial visit (assessed by clinician, blood for CD4 test taken) 6.61 6.13 7.48 6.74
ART eligibility assessment visit 6.04 5.10 6.96 6.04
Sick visit e.g. patient self-referred and seen by clinician* 6.04 5.10 6.96 6.04
6-monthly clinic (reassessed by clinician, blood sample for CD4 test taken)** 6.61 6.13 7.48 6.74
Routine follow up visit e.g. drug pick up and not seen by clinician 5.89 4.75 6.65 5.76
Costs of diagnostic tests in addition to outpatient visit costs
CD4 count test 15.83 14.75 16.72 15.76
Alanine aminotransferase (ALAT) test 0.88 0.84 0.91 0.88
Creatinine test 0.32 0.28 0.35 0.31
Haemoglobin (Hb) test 0.83 0.86 0.91 0.87
Random blood glucose (RBG) test 0.85 0.81 0.89 0.85
Venereal disease reference laboratory (VDRL) test 1.88 1.88 1.89 1.89
Pregnancy test 0.53 0.53 0.53 0.53
Full Blood Count (FBC) test 2.06 1.79 2.29 2.04
Serum cryptococcal meningitis (CRAG) test 5.00 2.68 4.19 3.96
Costs of the service components performed outside the clinic
Xpert testb 19.07
Collection and processing of cerebral spinal fluidc 16.29
Chest x-rayd 3.18
Lay worker visit to the patients home 14.74
Information obtained from the literature
Smear microscopy test 1.81
Sputum culture (Lowenstein Jensen) for TB [25] 6.84
ART regimens[15] (costs for daily dose)
d4T + 3TC +NVP 0.16
d4T + 3TC + EFV 0.28
AZT + 3TC +NVP 0.31
AZT + 3TC + EFV 0.61
TDF + 3TC + NVP 0.32
TDF + 3TC + EFV 0.60
ABC +3TC + NVP 0.13
ABC +3TC + EFV 0.76
TDF + FTC + EFV 0.60
TDF + FTC + NVP 0.48
TDF + FTC + ABC 0.84
Fluoconazole per a dose of 10 weeks 4.80
Cotrimoxazole per daily dose 0.02
District Hospital inpatient bed day[36] 26.45
Regional Hospital inpatient bed day[36] 24.72
Tertiary Hospital inpatient bed daye 24.01
(Continued )
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AZT, respectively, and 2% was spent on other regimens. Forty-four of 388 (11%) patients who
were initiated on ART substituted at least one drug in their regimen during the one year period
of follow up. Patients in the intervention arm were on co-trimoxazole for a mean of 0.74 years
during the study period. Compared to patients in standard care, patients in the intervention
Table 2. (Continued)
Variable Unit cost (2012 US$) (per patient)
Buguruni Mbagala Tandale Mean cost for all sites
TB treatment (6 monthly dose) 225
* Involves similar activities and therefore unit costs were assumed to be the same as for the ART eligibility assessment visit
** Involves similar activities and therefore unit costs were assumed to be the same as for the initial visit.
bPerformed at the Central TB laboratory
cDone at Muhimbili National Hospital
dperformed at the respective district hospital
eCosts for tertiary hospital were not available; we therefore assumed these costs were the same as those of the regional hospital
doi:10.1371/journal.pone.0171917.t002
Table 3. Unit costs (in 2012 US$), average quantity of resources utilized over 12 months of treatment and mean annual cost per patient, for
patients initiating treatment with CD4 count <200 cells/mm3 in Dar es Salaam, Tanzania.
Item Unit cost (US
$2012)
Mean? resource
utilisation per person
Cost per patient (US$2012) Difference
(Intervention—control)
Intervention Standard
care
Intervention
arm
Standard
care
Out patients visits
Initial visits 6.74 1.05 1.03 7.08 6.94 0.13
ART eligibility assessment visits 6.04 1.00 1.00 6.04 6.04 0.00
Sick visits 6.04 0.17 0.10 1.03 0.60 0.42
6-montly clinic review 6.74 0.89 0.86 6.00 5.80 0.20
Routine follow up visits 5.76 4.43 4.41 25.52 25.40 0.12
CD4 count test 15.72 1.60 1.56 25.15 24.52 0.63
ALT test 0.88 1.20 1.1 1.05 0.97 0.09
Creatinine test 0.31 0.77 0.74 0.24 0.23 0.01
Hb test 0.87 1.33 1.17 1.16 1.02 0.14
VDRL test 1.89 0.07 0.06 0.13 0.11 0.02
Pregnancy test 0.53 0.07 0.08 0.04 0.04 -0.01
Second Xpert test 19.07 0.88 0.00 16.78 0.00 16.78
Chest x-ray 3.18 0.06 0.05 0.17 0.16 0.02
CrAg test 8.43 1.00 0.00 8.43 0.00 8.43
Lay worker visit to the patients home 14.74 2.89 0.00 42.60 0.00 42.60
Collection and processing of cerebral spinal fluid 16.27 0.02 0.00 0.37 0.00 0.37
Days on ART drugs 0.42 323.12 213.60 135.71 131.71 4.00
Days on Co-trimoxazole 0.02 270.22 265.19 5.40 5.30 0.10
Days of hospital admissions 26.43 3.79 4.08 100.13 107.78 -7.66
Number of people put on fluconazole 4.8 0.09 0.00 0.43 0.00 0.43
Mean cost per patient during the first three
months and one year in treatment (in 2012US$)
First three months in treatment, mean (95% CI) 166 (161–171) 107 (101–
112)
59 (52–66)
One year in treatment, mean (95% CI) 331 (319–344) 265 (254–
275)
67(50–83)
doi:10.1371/journal.pone.0171917.t003
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arm had significantly more sick clinic visits (p = 0.001), alanine aminotransferase tests
(p = 0.039), and Hb tests (p = 0.0013).
Average costs per patient for routine care
The mean cost per patient year was US$ 265 (95% CI 254–275) in the standard care arm
(Table 3). ART drugs, clinic visits, hospital admission, diagnostic tests and non-ART drugs
constituted 50%, 19%, 19%, 10% and 2% of the total cost per patient year respectively (Fig 2).
Initial high costs of US$71 per patient month in the first month fell to US$ 30 per patient
month at 12 months (see Fig 3). The cost per patient was US$107 (101–112) in the first quarter,
after which it fell and stabilised at between $45 and $59 per quarter.
The mean annual cost of ART per participant varied from $34.89 for stavudine-based regi-
mens to $140.60 for tenofovir-based regimens. Costs of co-trimoxazole prophylaxis were just
over $5 per patient per year. Routine follow up visits were more common than other visits and
consequently accounted for a higher cost than other visits. CD4 count and the Xpert testing
were the most expensive laboratory tests, with serum CrAg testing costing just under $4 per
test per patient. Hospital admission costs exceed $43 per admission and comprised a mean of
4.87 days of inpatient care per patient.
Table 3 also compares the costs in the standard and intervention arms. The cost of adding
CrAg screening, home visits by lay-workers and a second Xpert test, as implemented in the
clinic plus community support arm of the trial, were US$ 8.43, US$42.60 and US$16.78 per
patient, respectively (see Table 3). The incremental costs per patient of the full intervention to
Fig 2. The cost breakdown of ART services by month for patients initiating treatment with CD4 count <200 cells/mm3 in Tanzania
for standard care.
doi:10.1371/journal.pone.0171917.g002
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the health service over the first three months was US$ 59 (p<0.001; 95%CI 51.5–66.5) and
over a one year period was US$ 67(p<0.001; 95%CI 50.0–83.2). This is equivalent to a 55%
(95%CI 50.7%–59.2%) increase in the mean cost of care over the first three months and a 25%
(95%CI 19.7%–30.2%) increase over one year of follow up.
Sensitivity analyses
The cost of care was robust to changes in the variables explored in the sensitivity analysis,
except to changes in the average number of home visits made by lay worker in a day, costs of
clinic visits involving a CD4 test and the cost of antiretroviral drugs. A 25% decrease in the
price of antiretroviral drugs led to a reduction in the mean costs per patient year of 10.6%,
and an increase in the number of home visits from 1.4 to 4 per day resulted in a 22% reduc-
tion in the additional cost for the intervention component during the first three months,
and a 12% over a one year period of follow up, whereas, an increase of costs for clinic visits
involving a CD4 test, by 50%, during the first three month of ART led to an increase in the
mean costs per patient year of 22.7%. A decrease in this by 50% resulted in a reduction of per
patient cost by 11.4%, (Table 4).
Regression
Table 5 reports on the results of the univariate and multivariate regression analyses of factors
that could influence health service costs in the standard care arm. None of the factors was sig-
nificantly associated with health service costs.
Fig 3. Mean cost (in USD 2012) per patient month for patients initiating ART treatment with CD4 count <200 cells/mm3 in
Tanzania for both standard care (control) and the REMSTART trial intervention arms.
doi:10.1371/journal.pone.0171917.g003
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Discussion
The costs of antiretroviral therapy in Africa have fallen remarkably. Nonetheless, as this study
demonstrates, the average cost of care remains high at nearly $300 per patient per year and
over half of this expenditure was on drugs. Using a micro costing approach, this study has cal-
culated the average cost per patient year of ART as well as the incremental cost of an innova-
tive intervention able to reduce mortality in ART patients. The analysis shows how costs fall
over time and that ART drugs continue to take up the largest share of ART costs. We did not
calculate the costs incurred by patients to access care, but previous studies have found these to
be remarkably high [37]. It is evident, that HIV continues to be a substantial burden in Africa.
The costs of the clinic plus community support intervention, which mostly targeted the first
month of ART, and which reduced all-cause mortality substantially [17], were about 25%
Table 4. Results of the sensitivity analyses exploring the impact of uncertainty in key variables on the average cost estimates for patients initiat-
ing ART treatment with CD4 count <200 cells/mm3 in Dar es Salaam, Tanzania.
Arm Parameters varied Varied values US$ (% divergence from base case)
1st three month Per Patient Year
Minimum Maximum Minimum Maximum Minimum Maximum
Standard
care
Base case* 106.9 106.9 264.7 264.7
Discount rate 1% 12% 106.3
(0.6)
107.3 (0.4) 263.4
(0.5)
265.8 (0.4)
Administrative costs 3% 15.5% 104.8
(2.0)
108.4 (1.4) 262.6
(0.8)
266.3 (0.6)
Costs for supporting staff -50% +50% 104.1
(2.6)
112.5 (5.2) 261.5
(1.2)
271.2 (2.4)
Costs for clinic visits involving a CD4 test -50% +50% 94.7
(11.4)
131.2 (22.7) 259.9
(1.8)
274.2 (3.6)
Costs for clinic visits involving seeing a clinician -50% +50% 103.7
(3.0)
113.2 (5.9) 262.3
(0.9)
269.5 (1.8)
Costs for routine follow up -50% +50% 106.8
(0.1)
124.1 (16.1) 255.7
(3.4)
268.9 (1.6)
Costs for Xpert -5% -25% 106.0
(0.8)
102.4 (4.2) 263.9
(0.3)
268.1 (1.3)
Price for Xpert cartridge -5% -25% 106.4
(0.5)
104.2 (2.5) 264.2
(0.2)
262.6 (0.8)
Costs for transport for Xpert sputum sample 0% -50% 106.4
(0.5)
106.6 (0.3) 264,2
(0.2)
264.4 (0.1)
Price of ARV -5% -25% 104.8
(2.0)
96.3 (9.9) 259.1
(2.1)
236.6 (10.6)
Costs for sputum smear microscopy 0% 100% 106.9
(0.0)
105.5**
(1.5)
264.7
(0.0)
262.3**
(0.9)
Intervention Base case* 165.9 165.9 331.4 331.4
Price for CRAG reagents -5% -25% 165.9
(0.0)
165.9 (0.0) 331.4
(0.0)
331.4 (0.0)
Monthly salary for lay workers US$177 US$383 156.6
(5.6)
165.9 (0.0) 325.1
(1.9)
334.4 (0.9)
Monthly income (salary & benefits) for lab technician for
processing the cerebral spinal fluid
US$379 US$397 165.7
(0.1)
166.1 (0.1) 331.4
(0.0)
331.5 (0.0)
Number of home visits by lay-worker 1 4 174.1
(4.9)
129.2 (22.1) 335.4
(1.2)
290.5 (12.3)
*Does not include costs for smear tests
**Does not include costs for Xpert test
doi:10.1371/journal.pone.0171917.t004
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higher than the standard treatment arm, when calculated over a 12-month period. The analysis
by month and by quarter confirm that the increase in cost is only associated with the initial
stage of treatment and as such do not have a major impact on the lifetime costs of ART, pro-
viding a strong argument for investment given the likely reduction in mortality that was dem-
onstrated by the trial. Although this study was done as part of a trial, it was integrated into the
health system, with patients managed by routine health care staff. Thus the costs presented are
likely to be typical of urban clinics in Tanzania among HIV-infected individuals presenting
with advanced disease. However, a formal economic evaluation is needed to determine if and
to what extent this intervention is cost-effective compared to standard care.
The cost of a single home visit was nearly $15, just over twice the cost incurred by health
services when a patient visits the clinic for routine care and similar to the cost of a CD4 count
test. The cost of home visits may be lower in real life settings if lay-workers can visit a greater
number patients per day. In our trial, most patients (in both arms) were initiated on ART on
their second visit to clinic, within a median of about two weeks [17], because we introduced
expedited initiation of antiretroviral therapy, whereas in most African HIV programmes,
patients are required to attend 3–4 times before ART is initiated. Our study demonstrates that
these early pre initiation visits are probably unnecessary and that it would be better to provide
additional support after the patient has started antiretroviral therapy.
Another striking finding was that the care delivered by the clinics differed substantially
from guidelines. The mean number of clinic visits involving a clinician was less than 2 visits
per patient during the first year on antiretroviral therapy, compared to the recommended 6
visits [20,32,38]; and CD4 count and safety blood testing were done much less frequently
Table 5. Univariate and multivariate regression (Generalized Linear model) analyses of factors that could influence ART service costs (in 2012 US
$) for patients initiating treatment with CD4 count <200 cells/mm3 in Dar es Salaam, Tanzania.
Independent variable Results of the Generalized Linear regression analyses (N = 870)
Univariate analysis F-test Multiple regression¥ F-test
*Coefficient (95% CI) p-value Coefficient (95% CI)* p-value
Age (reference is “Age less than 45years”) 0.5415 0.2702
 45 years 7.71 (-17.03–32.44) 14.67 (-11.38–40.66)
Level of CD4 count at enrolment (reference is “CD4 <25cells/mm3” 0.3698 0.3984
CD4 25–49cells/mm3 20.57 (-10.75–51.90) 20.83 (-10.94–52.59)
CD450cells/mm3 13.64 (-10.37–37.65) 12.17 (-12.20–36.54)
WHO clinical stage at enrolment (reference is “WHO stage 1 or 2”) 0.9154
WHO stage 3 or 4 -4.94 (-32.50–22.62) 0.7254 -1.54 (-29.98–26.90)
Sex 0.1168
Female 11.70 (-10.08–33.49) 0.2924 18.70 (-4.67–42.06)
Level of education (reference is “no formal education”) 0.4358 0.3954
Primary 19.45 (-10.26–49.16) 20.98 (-9.78–51.73)
Secondary and above 17.79 (-20.78–56.37) 21.36 (-18.35–61.07)
Clinic (reference is (“Buguruni clinic”) 0.1036 0.1284
Tandale clinic 18.46 (-10.53–47.45) 22.63 (-7.15–52.42)
Mbagala clinic -7.89 (-35.08–19.31) -1.88 (-29.92–26.17)
Marital status (reference is “married or living with someone” 0.9545 0.8574
Widowed/separated/divorced -2.45 (-26.08–21.18) -5.60 (-29.82–19.70)
Never married -4.33 (-34.44–25.78) -7.91 (-39.33–23.52)
¥All variables included simultaneously in a single model
*Mean difference in health service costs (in US$) compared to the reference group
doi:10.1371/journal.pone.0171917.t005
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than recommended. It is possible that this was because of shortages of staff and reagents, that
patients were not returning for required visits or that clinics felt that these visits were not
necessary.
The average cost per patient year of standard care in this study was marginally higher than
that reported from Zambia [11] and Nigeria [12], although the Nigeria study excluded over-
head costs. In accordance with our findings, in other studies conducted across Africa, antire-
troviral drugs have been the most expensive component of care [9–14,16]. We found that
reducing the price of antiretroviral drugs by 25% lowers the annual cost per patient by 11%;
this highlights the importance of international efforts to negotiate reductions in antiretroviral
drugs prices.
Initially, our study enrolled patients with CD4 count <100 cells/mm3, but this criteria was
changed subsequently to enrol patients presenting with<200 cells/mm3, in order to speed up
recruitment. This change affected both trial arms equally. and presumably was not felt to com-
promise the interpretation of the study from a clinical standpoint. The univariate and multi-
variate regression analyses of factors that could influence health service costs, the level of CD4
count was not significantly associated with health service costs, so it is unlikely this change had
any effect on the cost estimate.
Our study was conducted among urban patients with advanced disease. Whether the find-
ings are generalizable to rural patients, who are usually more geographically scattered and less
mobile, or among patients initiating ART in the early stages of HIV-infection needs further
research. We used university graduates as the lay workers and it is not clear if using lay-work-
ers with fewer qualifications would have the same effect. This needs further research as it may
be difficult to scale-up the programme using university graduates.
Conclusion
Micro costing approaches provide a way to obtain an in-depth understanding of cost struc-
tures and cost variation between individuals as well as over time. This study confirms that
despite price reductions, antiretroviral drugs constitute half of the cost of care for people
newly starting on ART and confirms that monthly costs of ART decline after the first month
of treatment. The added costs of the clinic plus community support intervention, which mostly
targets the first month, and which substantially reduced all-cause mortality, represented only a
small increase in life time ART costs, suggesting this important innovation in ART could be an
affordable approach to improving HIV care in resource constrained settings.
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